Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Reexamination Certificate
2005-08-25
2009-06-23
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
C514S018700, C514S019300, C548S535000
Reexamination Certificate
active
07550559
ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 6608027 (2003-08-01), Tsantrizos et al.
patent: 6995174 (2006-02-01), Wang et al.
patent: 0 381 216 (1995-12-01), None
patent: WO 89/04669 (1989-06-01), None
patent: WO 98/14181 (1998-04-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/22496 (1998-05-01), None
patent: WO 99/07734 (1999-02-01), None
patent: WO 00/09543 (2000-02-01), None
patent: WO 00/09558 (2000-02-01), None
patent: WO 00/59929 (2000-10-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/74768 (2001-10-01), None
patent: WO 01/77113 (2001-10-01), None
patent: WO 01/81325 (2001-11-01), None
patent: WO 02/08187 (2002-01-01), None
patent: WO 02/08198 (2002-01-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/08251 (2002-01-01), None
patent: WO 02/08256 (2002-01-01), None
patent: WO 02/48172 (2002-06-01), None
patent: WO 02/060926 (2002-08-01), None
patent: WO 2005/021584 (2005-03-01), None
International Search Report for International Application No. PCT/US2005/030249 mailed Feb. 3, 2006—4pgs.
Berenguer, Marina, et al., “Hepatitis B and C . . . ,” Proceedings of the Association of American Physicians 110(2):98-112 (1998).
Dimasi, Nazzareno, et al., “Characterization of Engineered . . . ,” Journal of Virology 71(10):7461-69 (1997).
Elzouki, Abdul-Nasser, et al., “Serine protease inhibitors . . . ,” Journal of Hepatology 27:42-48 (1997).
Failla, Cristina Maria, et al., “Redesigning the substrate . . . ,” Folding & Design 1(1):35-42 (Jan. 10, 1996).
Han, Wei, et al., “alpha-Ketoamides, alpha-Ketoesters . . . ,” Bioorganic & Medicinal Chemistry Letters 10:711-713 (2000).
Hoofnagle, Jay H., et al., “The Treatment of . . . ,” Drug Therapy 336(5):347-56 (1997).
Ingallinella, Paolo, et al., “Potent Peptide Inhibitors . . . ,” Biochemistry 37:8906-14 (1998).
Johansson, Anja, et al., “Tetrapeptides as Potent . . . ,” Bioorganic & Medicinal Chemistry 3915-3922 (2002).
Johansson, Anja, et al., “Acyl Sulfonamides as Potent . . . ,” Bioorganic & Medicinal Chemistry 11:2551-68 (2003).
Kolykhalov, Alexander A., et al., “Specificy of the Hepatitis . . . ,” Journal of Virology 68(11):7525-7533 (Nov. 1994).
Komoda, Yasumasa, et al., “Substrate Requirements of Hepatitis C . . . ,” Journal of Virology 68(11)7351-7 (Nov. 1994).
Landro, James A., et al., “Mechanistic Role of . . . ,” Biochemistry 36:9340-8 (1997).
Llinas-Brunet, Montse, et al., “Peptide-Based Inhibitors . . . ,” Bioorganic & Medicinal Chemistry Letters 8:1713-1718 (1998).
Marchetti, Antonella, et al., “Synthesis of Two Novel . . . ,” Synlett S1:1000-1002 (1999).
Martin, F., et al., “Affinity selection of a . . . ,” Protein Engineering 10(5):607-14 (1997).
Martin, Franck, et al., “Design of Selective . . . ,” Biochemistry 37:11459-68 (1998).
Pizzi, Elisabetta, et al., “Molecular model of . . . ,” Proc. Natl. Acad. Sci. USA 91:888-892 (Feb. 1994).
BioWorld Today 9(217):4 (Nov. 10, 1998).
U.S. Appl. No. 10/052,386, filed Jan. 18, 2002.
Girijavallabhan Viyyoor M.
Njoroge F. George
Sannigrahi Mousumi
Farquharson-Torres Serena
Kalyanaraman Palaiyur S.
Lukton David
Schering Corporation
LandOfFree
Acylsulfonamide compounds as inhibitors of hepatitis C virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Acylsulfonamide compounds as inhibitors of hepatitis C virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylsulfonamide compounds as inhibitors of hepatitis C virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098049